In accordance with the Drugs(Prices Control) Order 2013, the NPPA has increased the ceiling prices of 883 scheduled formulations.
The Authority held a meeting on 31st March, 2020 in which it concluded that the supply disruption of APIs caused by COVID-19 outbreak is returning to its normal conditions and no unusual price fluctuations in the price of inputs for medicines, amid the COVID-19 outbreak has been reported. Therefore, price revisions are to be allowed.
The increase in prices is based on the Wholesale Price Index(WPI) which is 1.88468 percent, which is based on the data published by the Department for Promotion of Industry and Internal Trade, Ministry of Commerce and Industry, Government of India. The revised prices will be applicable from 1st April 2020.